News and Analysis | Published:

'Party drug' turned antidepressant approaches approval

Nature Reviews Drug Discovery volume 17, pages 773775 (2018) | Download Citation

Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2018.187

Authors

  1. Search for Sara Reardon in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing